|Articles|May 1, 2001
- Pharmaceutical Executive-05-01-2001
- Volume 0
- Issue 0
Friends of Complexity
Author(s)Wayne Koberstein
Pharmaceutical executives should study their own scientists. They construct clever tools to explore convoluted phenomena. They are the true friends of complexity.
Advertisement
Articles in this issue
over 24 years ago
Policy: Task Mastersover 24 years ago
Pharmacia's Carrie Cox: HBA Woman of the Yearover 24 years ago
Under Federal Fireover 24 years ago
Task Force: Enter the Fixersover 24 years ago
The Next Y2Kover 24 years ago
Political ScienceNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Targeting CCR5 Receptors
2
Merck to Acquire Cidara for $9.2 Billion
3
Komzifti Gains FDA Approval, Giving Kura Oncology and Kyowa Kirin a Key Strategic Win in NPM1-Mutated AML
4
DEI Changes in Pharma: A Look Back at 2025 & Predictions for 2026
5
